Biogen’s failure of its Alzheimer’s drug, Aduhelm has led to a CEO change with the company looking for a successor to CEO Michael Vounatsos. The company’s MS business generated $1.6 billion in revenue, including Ocrevus royalties in the last quarter and has been performing fairly well. However, they have built a $1 billion dollar cost-saving plan and are significantly reducing spending on Aduhelm as part of designed to refocus the company’s flagging biotech business. The management sees the pote ....
21 May 2022
Biogen Inc.: Financial & Price Forecasts, DCF & Comparables Valuation, ESG & Other Risks (05/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Biogen Inc.: Financial & Price Forecasts, DCF & Comparables Valuation, ESG & Other Risks (05/22)
- Published:
21 May 2022 -
Author:
Ishan Majumdar -
Pages:
26
Biogen’s failure of its Alzheimer’s drug, Aduhelm has led to a CEO change with the company looking for a successor to CEO Michael Vounatsos. The company’s MS business generated $1.6 billion in revenue, including Ocrevus royalties in the last quarter and has been performing fairly well. However, they have built a $1 billion dollar cost-saving plan and are significantly reducing spending on Aduhelm as part of designed to refocus the company’s flagging biotech business. The management sees the pote ....